

**RECEIVED  
CENTRAL FAX CENTER**

MAR-18-2005 14:45

PRONEURON

240 683 3794 P.05

MAR 18 2005

PTO/SB/028 (08-03)

Approved for use through 6/30/2006, OMB 0451-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete &amp; Known</b>	
		Application Number	10/717,101
		Filing Date	November 19, 2003
		First Named Inventor	Harold Atkins
		Art Unit	1648
		Examiner Name	Bao Q. Li
Attorney Docket Number	18013-C1		
Sheet 1	of 1		

DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BLi		U.S. Application Number 10/743,639, claims 1-2 and 5-7, 10-21-2004 US 2004 0208849 A1 Bell et al.	Baogun L.
BLi		U.S. Application Number 10/743,649, claims 1 and 4-6, 09-02-2004 US 2004 0170607 A1, Bell et al.	Baogun L. 10/18/2006

Examiner Signature	<i>Baogun L.</i>	Date Considered	03/18/2008
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial & reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**FEB 05 2004**

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/717,101	
			Filing Date	November 19, 2003	
			First Named Inventor	Harold L. Atkins	
			Art Unit	1648	
			Examiner Name	Bao Q. Li	
			Attorney Docket Number	18013-C1	
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	/Bao Li/ (10/30/2006)	Date Considered	10/30/2006
-----------------------	-----------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind's Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Business Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
		Application Number	10/717,101
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Filing Date	November 19, 2003
		First Named Inventor	Harold L. Atkins
		Group Art Unit	1648
		Examiner Name	Bao Q. Li
		Attorney Docket Number	18013-C1
Sheet	2	of	2

NON PATENT PUBLICATIONS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
BL ↓ V		Belch, et al., "Novel therapeutic strategies in multiple myeloma (MM): Use of shiga-like toxin (SLT) or reovirus to purge myeloma cells", Blood, Vol. 92, No. 10 suppl. 1 Part 1-2, pages 104A-105A, November 1998.	
		Seth, et al., "Adenovirus-mediated Gene Transfer to Human Breast Tumor Cells: An Approach for Cancer Gene Therapy and Bone Marrow Purging", Cancer Research, Vol. 56, No. 6, pages 1346-1351, March 15, 1996.	
		Wu, et al., "Bone Marrow Purging of Neuroblastoma by Attenuated Multimutated Herpes Simplex Virus", Proceedings of the American Association for Cancer Research Annual, Vol. 39, page 605, March 1998. (Abstract #4113)	
		Lichty, et al., "Identification of vesicular stomatitis virus as a leukemolytic agent", Blood, Vol. 96, No. 11 Part 2, page 213b, November 2000.	
		Stojdl, et al., "Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus", Nature Medicine, Vol. 6, No. 7, pages 821-825, July 2000.	
		Bell, et al., U.S. Serial No. 09/664,444, "Oncolytic Virus," (filed September 18, 2001)	
		Sinkovics, et al., J. Clin. Virol. Vol. 16, pages 1-15, 2000.	
		Baton, et al., Proc. Soc. Exp. Biol. Med. Vol 132, pages 20-26, 1969.	

Examiner Signature	/Bao Li/ (10/30/2006)	Date Considered	10/30/2006
--------------------	-----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.